Sara Lodi | Profiles RNS

Sara Lodi, PhD

Assistant Professor

Boston University School of Public Health

Dept of Biostatistics

PhD, London School of Hygiene & Tropical Medicine
MSc, University of Southampton

Sara Lodi is an Assistant Professor in Biostatistics at Boston University School of Public Heath. She obtained her PhD in Medical Statistics at the London School of Hygiene and Tropical Medicine in 2009, UK. Her research focuses on clinical epidemiology and comparative effectiveness research using routinely collected heath data, particularly in the area of HIV. Methodologically, she focuses on statistical techniques for causal inference to estimate effects of interventions along the HIV continuum of care. She has published many articles on behalf of large international collaborations of HIV cohorts such as CASCADE, COHERE and the HIV-CAUSAL Collaboration.

BU Research

Interventions to reduce alcohol use and increase adherence to TB preventive therapy among HIV/TB co-infected drinkers - 1/2
09/15/2017 - 08/31/2022 (Subcontract PI)
The Regents of the University of California, San Francisco NIH NIAAA
5U01AA026223-03

Stigma, Risk Behaviors and Health care among HIV-Infected Russian People Who Inject Drugs
09/01/2018 - 08/31/2019 (Subcontract PI)
Boston Medical Center Corporation NIH NIDA
4R00DA041245-03

Forecasting the Impact of Correction-based MOUD in Massachusetts (FICOMM)
12/01/2017 - 11/30/2018 (Subcontract PI)
Boston Medical Center Corporation OffNtlDrugCtrlPolicy

Title

Yr	Title	Project-Sub Proj	Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis Copy PMIDs To Clipboard

Kimmel SD, Walley AY, Li Y, Linas BP, Lodi S, Bernson D, Weiss RD, Samet JH, Larochelle MR. Association of Treatment With Medications for Opioid Use Disorder With Mortality After Hospitalization for Injection Drug Use-Associated Infective Endocarditis. JAMA Netw Open. 2020 Oct 01; 3(10):e2016228.View Related Profiles.

Walley, Alexander
Linas, Benjamin
Samet, Jeffrey
Larochelle, Marc
Lodi, Sara
Kimmel, Simeon

PMID: 33052402; DOI: 10.1001/jamanetworkopen.2020.16228;

Puryear SB, Fatch R, Beesiga B, Kekibiina A, Lodi S, Marson K, Emenyonu NI, Muyindike WR, Kwarisiima D, Hahn JA, Chamie G. Higher levels of alcohol use are associated with latent tuberculosis infection in adults living with HIV. Clin Infect Dis. 2020 May 06. PMID: 32374867

Serota DP, Capozzi C, Lodi S, Colasanti JA, Forman LS, Tsui JI, Walley AY, Lira MC, Samet J, Del Rio C, Merlin JS. Predictors of pain-related functional impairment among people living with HIV on long-term opioid therapy. AIDS Care. 2020 Apr 03; 1-9.View Related Profiles.

Walley, Alexander
Samet, Jeffrey
Lodi, Sara

PMID: 32242463

Walley AY, Lodi S, Li Y, Bernson D, Babakhanlou-Chase H, Land T, Larochelle MR. Association between mortality rates and medication and residential treatment after in-patient medically managed opioid withdrawal: a cohort analysis. Addiction. 2020 08; 115(8):1496-1508.View Related Profiles.

Walley, Alexander
Larochelle, Marc
Lodi, Sara

PMID: 32096908

Lodi S, Günthard HF, Gill J, Phillips AN, Dunn D, Vu Q, Siemieniuk R, Garcia F, Logan R, Jose S, Bucher HC, Scherrer AU, Reiss P, van Sighem A, Boender TS, Porter K, Gilson R, Paraskevis D, Simeon M, Vourli G, Moreno S, Jarrin I, Sabin C, Hernán MA. Effectiveness of Transmitted Drug Resistance Testing Before Initiation of Antiretroviral Therapy in HIV-Positive Individuals. J Acquir Immune Defic Syndr. 2019 11 01; 82(3):314-320. PMID: 31609929

Conner SC, Lodi S, Lunetta KL, Casas JP, Lubitz SA, Ellinor PT, Anderson CD, Huang Q, Coleman J, White WB, Benjamin EJ, Trinquart L. Refining the Association Between Body Mass Index and Atrial Fibrillation: G-Formula and Restricted Mean Survival Times. J Am Heart Assoc. 2019 08 20; 8(16):e013011.View Related Profiles.

Benjamin, Emelia
Lunetta, Kathryn
Trinquart, Ludovic
Lodi, Sara

PMID: 31390924

Lodi S, Phillips A, Lundgren J, Logan R, Sharma S, Cole SR, Babiker A, Law M, Chu H, Byrne D, Horban A, Sterne JAC, Porter K, Sabin C, Costagliola D, Abgrall S, Gill J, Touloumi G, Pacheco AG, van Sighem A, Reiss P, Bucher HC, Montoliu Giménez A, Jarrin I, Wittkop L, Meyer L, Perez-Hoyos S, Justice A, Neaton JD, Hernán MA. Effect Estimates in Randomized Trials and Observational Studies: Comparing Apples With Apples. Am J Epidemiol. 2019 08 01; 188(8):1569-1577. PMID: 31063192

Lodi S, Günthard HF, Dunn D, Garcia F, Logan R, Jose S, Bucher HC, Scherrer AU, Schneider MP, Egger M, Glass TR, Reiss P, van Sighem A, Boender TS, Phillips AN, Porter K, Hawkins D, Moreno S, Monge S, Paraskevis D, Simeon M, Vourli G, Sabin C, Hernán MA. Effect of immediate initiation of antiretroviral treatment on the risk of acquired HIV drug resistance. AIDS. 2018 01 28; 32(3):327-335. PMID: 29135583

Caniglia EC, Phillips A, Porter K, Sabin CA, Winston A, Logan R, Gill J, Vandenhende MA, Barger D, Lodi S, Moreno S, Arribas JR, Pacheco A, Cardoso SW, Chrysos G, Gogos C, Abgrall S, Costagliola D, Meyer L, Seng R, van Sighem A, Reiss P, Muga R, Hoyos SP, Braun D, Hauser C, Barrufet P, Leyes M, Tate J, Justice A, Hernán MA. Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological Conditions. J Acquir Immune Defic Syndr. 2018 Jan 01; 77(1):102-109. PMID: 28991888

Murray EJ, Robins JM, Seage GR, Lodi S, Hyle EP, Reddy KP, Freedberg KA, Hernán MA. Using Observational Data to Calibrate Simulation Models. Med Decis Making. 2018 02; 38(2):212-224.View Related Profiles.

Murray, Eleanor
Seage, George
Lodi, Sara

PMID: 29141153

Showing 10 of 39 results. Show More

Lodi S, Costagliola D, Sabin C, Del Amo J, Logan R, Abgrall S, Reiss P, van Sighem A, Jose S, Blanco JR, Hernando V, Bucher HC, Kovari H, Segura F, Ambrosioni J, Gogos CA, Pantazis N, Dabis F, Vandenhende MA, Meyer L, Seng R, Gill MJ, Krentz H, Phillips AN, Porter K, Grinsztejn B, Pacheco AG, Muga R, Tate J, Justice A, Hernán MA. Effect of Immediate Initiation of Antiretroviral Treatment in HIV-Positive Individuals Aged 50 Years or Older. J Acquir Immune Defic Syndr. 2017 Nov 01; 76(3):311-318. PMID: 28746165

Inequalities by educational level in response to combination antiretroviral treatment and survival in HIV-positive men and women in Europe. AIDS. 2017 01 14; 31(2):253-262. PMID: 27662557; DOI: 10.1097/QAD.0000000000001270;

Lodi S, Sharma S, Lundgren JD, Phillips AN, Cole SR, Logan R, Agan BK, Babiker A, Klinker H, Chu H, Law M, Neaton JD, Hernán MA. The per-protocol effect of immediate versus deferred antiretroviral therapy initiation. AIDS. 2016 11 13; 30(17):2659-2663. PMID: 27782964

Lodi S, Sharma S, Lundgren JD, Phillips AN, Cole SR, Logan R, Agan BK, Babiker A, Klinker H, Chu H, Law M, Neaton JD, Hernán MA. The per-protocol effect of immediate vs. deferred ART initiation in the START randomized trial. AIDS. 2016 Sep 06. PMID: 27603292

Children and young people with perinatal HIV in Europe: epidemiological situation in 2014 and implications for the future. Euro Surveill. 2016; 21(10):30162. PMID: 26988197; DOI: 10.2807/1560-7917.ES.2016.21.10.30162;

Lodi S, Phillips A, Logan R, Olson A, Costagliola D, Abgrall S, van Sighem A, Reiss P, Miró JM, Ferrer E, Justice A, Gandhi N, Bucher HC, Furrer H, Moreno S, Monge S, Touloumi G, Pantazis N, Sterne J, Young JG, Meyer L, Seng R, Dabis F, Vandehende MA, Pérez-Hoyos S, Jarrín I, Jose S, Sabin C, Hernán MA. Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study. Lancet HIV. 2015 Aug; 2(8):e335-43. PMID: 26423376; PMCID: PMC4643831

Lodi S, del Amo J, Moreno S, Bucher HC, Furrer H, Logan R, Sterne J, Pérez-Hoyos S, Jarrín I, Phillips A, Olson A, van Sighem A, Reiss P, Sabin C, Jose S, Justice A, Goulet J, Miró JM, Ferrer E, Meyer L, Seng R, Vourli G, Antoniadou A, Dabis F, Vandenhede M, Costagliola D, Abgrall S, Hernán MA. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries. AIDS. 2014; 28(16):2461-73.

Lodi S, Dray-Spira R, Touloumi G, Braun D, Teira R, D'Arminio Monforte A, Gallois A, Zangerle R, Spire B, Dabis F, Stähelin C, Termote M, Kirk O, Chêne G, Egger M, del Amo J. Delayed HIV diagnosis and initiation of antiretroviral therapy: inequalities by educational level, COHERE in EuroCoord. AIDS. 2014 Sep 24; 28(15):2297-306. PMID: 25313585

van der Helm JJ, Geskus R, Lodi S, Meyer L, Schuitemaker H, Gunsenheimer-Bartmeyer B, Monforte Ad, Olson A, Touloumi G, Sabin C, Porter K, Prins M. Characterisation of long-term non-progression of HIV-1 infection after seroconversion: a cohort study. Lancet HIV. 2014 Oct; 1(1):e41-8. PMID: 26423816

Olson AD, Guiguet M, Zangerle R, Gill J, Perez-Hoyos S, Lodi S, Ghosn J, Dorrucci M, Johnson A, Sannes M, Moreno S, Porter K. Evaluation of rapid progressors in HIV infection as an extreme phenotype. J Acquir Immune Defic Syndr. 2014 Sep 01; 67(1):15-21. PMID: 24872130; PMCID: PMC4134321

Supervie V, Ndawinz JD, Lodi S, Costagliola D. The undiagnosed HIV epidemic in France and its implications for HIV screening strategies. AIDS. 2014 Jul 31; 28(12):1797-804. PMID: 24681416; PMCID: PMC4262966

Lodi S, Fisher M, Phillips A, De Luca A, Ghosn J, Malyuta R, Zangerle R, Moreno S, Vanhems P, Boufassa F, Guiguet M, Porter K. Symptomatic illness and low CD4 cell count at HIV seroconversion as markers of severe primary HIV infection. PLoS One. 2013; 8(11):e78642. PMID: 24244330; PMCID: PMC3828389

Lodi S, Phillips A, Fidler S, Hawkins D, Gilson R, McLean K, Fisher M, Post F, Johnson AM, Walker-Nthenda L, Dunn D, Porter K. Role of HIV infection duration and CD4 cell level at initiation of combination anti-retroviral therapy on risk of failure. PLoS One. 2013; 8(9):e75608. PMID: 24086588; PMCID: PMC3782426

Huang X, Lodi S, Fox Z, Li W, Phillips A, Porter K, Lutsar I, Kelleher A, Li N, Xu X, Wu H, Johnson AM. Rate of CD4 decline and HIV-RNA change following HIV seroconversion in men who have sex with men: a comparison between the Beijing PRIMO and CASCADE cohorts. J Acquir Immune Defic Syndr. 2013 Apr 01; 62(4):441-6. PMID: 23221982

Porter K, Lodi S, Meyer L. Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion--reply. JAMA Intern Med. 2013 Mar 25; 173(6):476-7. PMID: 23529555

Lodi S, del Amo J, d'Arminio Monforte A, Abgrall S, Sabin C, Morrison C, Furrer H, Muga R, Porter K, Girardi E. Risk of tuberculosis following HIV seroconversion in high-income countries. Thorax. 2013 Mar; 68(3):207-13. PMID: 23117980

Lodi S, Meyer L, Kelleher AD, Rosinska M, Ghosn J, Sannes M, Porter K. Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion. Arch Intern Med. 2012 Sep 10; 172(16):1252-5. PMID: 22826124

Cain LE, Phillips A, Lodi S, Sabin C, Bansi L, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, de Wolf F, Bucher HC, Elzi L, Touloumi G, Vourli G, Esteve A, Casabona J, del Amo J, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Abgrall S, Costagliola D, Hernán MA. The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study. AIDS. 2012 Aug 24; 26(13):1691-705. PMID: 22546987; PMCID: PMC3647467

del Amo J, Moreno S, Bucher HC, Furrer H, Logan R, Sterne J, Pérez-Hoyos S, Jarrín I, Phillips A, Lodi S, van Sighem A, de Wolf W, Sabin C, Bansi L, Justice A, Goulet J, Miró JM, Ferrer E, Meyer L, Seng R, Toulomi G, Gargalianos P, Costagliola D, Abgrall S, Hernán MA. Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries. Clin Infect Dis. 2012 May; 54(9):1364-72. PMID: 22460971; PMCID: PMC3404691

del Amo J, Moreno S, Bucher HC, Furrer H, Logan R, Sterne J, Pérez-Hoyos S, Jarrín I, Phillips A, Lodi S, van Sighem A, de Wolf F, Sabin C, Bansi L, Justice A, Goulet J, Miró JM, Ferrer E, Meyer L, Seng R, Toulomi G, Gargalianos P, Costagliola D, Abgrall S, Hernán MA. Clinical Infectious Diseases. 2012; 54:1364-1372.

Lodi S, Phillips A, Touloumi G, Geskus R, Meyer L, Thiébaut R, Pantazis N, Amo JD, Johnson AM, Babiker A, Porter K. Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds <200, <350, and <500 Cells/mm³: assessment of need following changes in treatment guidelines. Clin Infect Dis. 2011 Oct; 53(8):817-25. PMID: 21921225

Cain LE, Logan R, Robins JM, Sterne JA, Sabin C, Bansi L, Justice A, Goulet J, van Sighem A, de Wolf F, Bucher HC, von Wyl V, Esteve A, Casabona J, del Amo J, Moreno S, Seng R, Meyer L, Perez-Hoyos S, Muga R, Lodi S, Lanoy E, Costagliola D, Hernan MA. When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Ann Intern Med. 2011 Apr 19; 154(8):509-15. PMID: 21502648; PMCID: PMC3610527

Lodi S, Carpenter J, Egger P, Evans S. Design of cohort studies in chronic diseases using routinely collected databases when a prescription is used as surrogate outcome. BMC Med Res Methodol. 2011 Apr 01; 11:36. PMID: 21457565; PMCID: PMC3079701

Lodi S, Phillips A, Touloumi G, Geskus R, Meyer L, Thiebaut R, Pantazis N, del Amo J, Johnson A, Babiker A, Porter K. Time from HIV seroconversion to reaching CD4 thresholds of <200, <350 and <500 cells/mm3. Clinical Infectious diseases. 2011; 53:817-825.

Lodi S, Phillips A, Touloumi G, Pantazis N, Bucher HC, Babiker A, Chêne G, Vanhems P, Porter K. CD4 decline in seroconverter and seroprevalent individuals in the precombination of antiretroviral therapy era. AIDS. 2010 Nov 13; 24(17):2697-704. PMID: 20885283

Lodi S, Guiguet M, Costagliola D, Fisher M, de Luca A, Porter K. Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion. J Natl Cancer Inst. 2010 Jun 02; 102(11):784-92. PMID: 20442214

Ray M, Logan R, Sterne JA, Hernández-Díaz S, Robins JM, Sabin C, Bansi L, van Sighem A, de Wolf F, Costagliola D, Lanoy E, Bucher HC, von Wyl V, Esteve A, Casbona J, del Amo J, Moreno S, Justice A, Goulet J, Lodi S, Phillips A, Seng R, Meyer L, Pérez-Hoyos S, García de Olalla P, Hernán MA. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS. 2010 Jan 02; 24(1):123-37. PMID: 19770621; PMCID: PMC2920287

Lodi S, Evans SJ, Egger P, Carpenter J. Is there an anti-inflammatory effect of statins in rheumatoid arthritis? Analysis of a large routinely collected claims database. Br J Clin Pharmacol. 2010 Jan; 69(1):85-94. PMID: 20078616; PMCID: PMC2830601

Lodi S, Sebastiani P, Cocchi D, Ramoni. New Developments in Classification and Data Analysis, Springer Verlag (M. Vichi, P. Monari, S. Mignani, A. Montanari, Eds.). Bayesian clustering of gene expression dynamic: an application. 2004; 259-266.

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 39 publications over 12 distinct years, with a maximum of 5 publications in 2012 and 2014

Bar chart showing 39 publications over 12 distinct years, with a maximum of 5 publications in 2012 and 2014

Year	Publications
2004	1
2010	4
2011	4
2012	5
2013	4
2014	5
2015	1
2016	3
2017	3
2018	2
2019	3
2020	4

In addition to these self-described keywords below, a list of MeSH based concepts is available here.

HIV-1
Causality
Observational Studies

Contact for Mentoring:

801 Massachusetts Avenue
Boston MA 02118
Google Map

617.638.5160

Download vCard

Lodi's Networks

Click the "See All" links for more information and interactive visualizations

Concepts

See all (115) concept(s)

Co-Authors

See all (10) people

Similar People

See all (60) people

Same Department

Search Department